A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein
- PMID: 33482242
- PMCID: PMC7817443
- DOI: 10.1016/j.virusres.2021.198305
A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein
Abstract
In this study, we showed that a codon optimized version of the spike (S) protein of SARS-CoV-2 can migrate to the cell membrane. However, efficient production of Moloney murine leukemia (MLV) infectious viral particles was only achieved with stable expression of a shorter S version in C-terminal (ΔS) in MLV Gag-pol expressing cells. As compared to transient transfections, this platform generated viruses with a 1000-fold higher titer. ΔS was 15-times more efficiently incorporated into VLPs as compared to S, and that was not due to steric interference between the cytoplasmic tail and the MLV capsid, as similar differences were also observed with extracellular vesicles. The amount of ΔS incorporated into VLPs released from producer cells was high and estimated at 1.25 μg/mL S2 equivalent (S is comprised of S1 and S2). The resulting VLPs could potentially be used alone or as a boost of other immunization strategies for COVID-19.
Keywords: COVID-19; Coronavirus; Moloney; Retrovirus; SARS-CoV-2; VLP; Vaccine; Virus-like particle.
Copyright © 2021 Elsevier B.V. All rights reserved.
Conflict of interest statement
K.G, P.O. de C-L and M.C. are co-founders and shareholders of BioVec Pharma. M.C. is an author of a patent application covering the VLP platform presented in this study.
Figures






Similar articles
-
Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.J Virol. 2020 Oct 14;94(21):e01062-20. doi: 10.1128/JVI.01062-20. Print 2020 Oct 14. J Virol. 2020. PMID: 32788194 Free PMC article.
-
Pseudotyping Improves the Yield of Functional SARS-CoV-2 Virus-like Particles (VLPs) as Tools for Vaccine and Therapeutic Development.Int J Mol Sci. 2023 Sep 27;24(19):14622. doi: 10.3390/ijms241914622. Int J Mol Sci. 2023. PMID: 37834067 Free PMC article.
-
A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.Nat Commun. 2020 Dec 16;11(1):6402. doi: 10.1038/s41467-020-20228-7. Nat Commun. 2020. PMID: 33328475 Free PMC article.
-
Coronavirus Disease 2019 Vaccine Development: An Overview.Viral Immunol. 2021 Apr;34(3):134-144. doi: 10.1089/vim.2020.0119. Epub 2020 Sep 23. Viral Immunol. 2021. PMID: 32985963 Review.
-
Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.Viruses. 2021 Feb 9;13(2):270. doi: 10.3390/v13020270. Viruses. 2021. PMID: 33572452 Free PMC article. Review.
Cited by
-
An Efficient and Scalable Method for the Production of Immunogenic SARS-CoV-2 Virus-like Particles (VLP) from a Mammalian Suspension Cell Line.Vaccines (Basel). 2023 Sep 9;11(9):1469. doi: 10.3390/vaccines11091469. Vaccines (Basel). 2023. PMID: 37766145 Free PMC article.
-
COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response.Vaccines (Basel). 2020 Nov 3;8(4):649. doi: 10.3390/vaccines8040649. Vaccines (Basel). 2020. PMID: 33153096 Free PMC article. Review.
-
Single-particle quantification of SARS-CoV-2 virus-like particles using flow virometry.Arch Virol. 2025 Jun 7;170(7):149. doi: 10.1007/s00705-025-06339-w. Arch Virol. 2025. PMID: 40483334
-
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.Heliyon. 2024 Jul 20;10(15):e34927. doi: 10.1016/j.heliyon.2024.e34927. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39144987 Free PMC article. Review.
-
T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets.Front Immunol. 2023 Jun 14;14:1133225. doi: 10.3389/fimmu.2023.1133225. eCollection 2023. Front Immunol. 2023. PMID: 37388738 Free PMC article. Review.
References
-
- Cantin R., Diou J., Belanger D., Tremblay A.M., Gilbert C. Discrimination between exosomes and HIV-1: purification of both vesicles from cell-free supernatants. J. Immunol. Methods. 2008;338(1–2):21–30. - PubMed
-
- Crawford K.H.D., Eguia R., Dingens A.S., Loes A.N., Malone K.D., Wolf C.R., Chu H.Y., Tortorici M.A., Veesler D., Murphy M., Pettie D., King N.P., Balazs A.B., Bloom J.D. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses. 2020;12(5) - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous